News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
Listed IPO INSILICO Spikes 13% to Log New Listing High on $39M Milestone Payment Received Following First-in-patient Dosing for MEN2501
Listed IPO INSILICO (03696.HK), which focuses on AI drug discovery, opened 4.56% higher this morning (3rd) before its gains expanded in the morning session, and peaked at $68.7, lo...
Reset
Send
The window will close in 5 seconds
Listed IPO INSILICO Spikes 13% to Log New Listing High on $39M Milestone Payment Received Following First-in-patient Dosing for MEN2501
Close
Recommend
7
Positive
9
Negative
2
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

Listed IPO INSILICO (03696.HK)  -3.550 (-5.839%)    Short selling $54.48M; Ratio 67.797%   , which focuses on AI drug discovery, opened 4.56% higher this morning (3rd) before its gains expanded in the morning session, and peaked at $68.7, logging a new listing high. It last printed at $68.1, spiking 13.03%, with a trading volume of 1.5069 million shares, involving $100 million.

Before the market opened this morning, the Company announced that it has received approx. $39 million from Menarini Group as an additional milestone payment, following the completion of first-in-patient dosing in a Phase I clinical trial of MEN2501.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)

Related News Insilico Medicine (03696.HK) Expands Annual Loss to USD352 Million

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.